159 related articles for article (PubMed ID: 16888171)
1. Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation.
Delgado M; Chorny A; Ganea D; Gonzalez-Rey E
Ann N Y Acad Sci; 2006 Jul; 1070():226-32. PubMed ID: 16888171
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.
Chorny A; Gonzalez-Rey E; Fernandez-Martin A; Ganea D; Delgado M
Blood; 2006 May; 107(9):3787-94. PubMed ID: 16418327
[TBL] [Abstract][Full Text] [Related]
3. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
4. Predominant immature CD8alpha+ dendritic cells prevent graft-vs.-host disease but do not increase the risk of leukemia recurrence.
Xu L; Duan L; Cao K; Yuan G; Peng Y; Huang X; Xiang P; Li S
Eur J Haematol; 2007 Mar; 78(3):235-45. PubMed ID: 17253973
[TBL] [Abstract][Full Text] [Related]
5. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide.
Pozo D; Anderson P; Gonzalez-Rey E
J Immunol; 2009 Oct; 183(7):4346-59. PubMed ID: 19734220
[TBL] [Abstract][Full Text] [Related]
6. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
[TBL] [Abstract][Full Text] [Related]
9. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
Moyer JS; Maine G; Mulé JJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
[TBL] [Abstract][Full Text] [Related]
10. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
[TBL] [Abstract][Full Text] [Related]
11. [Experimental study on immunotherapy with dendritic cell in leukemic mice model].
Li XX; Chen XL; Ma DX; Liu CS; He XP
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):73-7. PubMed ID: 16732955
[TBL] [Abstract][Full Text] [Related]
12. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
13. Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation.
Chorny A; Gonzalez-Rey E; Delgado M
Ann N Y Acad Sci; 2006 Nov; 1088():187-94. PubMed ID: 17192565
[TBL] [Abstract][Full Text] [Related]
14. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
15. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease.
Maeda Y; Tawara I; Teshima T; Liu C; Hashimoto D; Matsuoka K; Tanimoto M; Reddy P
Exp Hematol; 2007 Feb; 35(2):274-86. PubMed ID: 17258076
[TBL] [Abstract][Full Text] [Related]
16. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
19. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
[TBL] [Abstract][Full Text] [Related]
20. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
